![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1404, 2003-01, pp. : 4-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
HAART accounts for large increase in HIV/AIDS costs in Canada
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 429, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Economic Costs to Business of the HIV/AIDS Epidemic
By Gordon G. Liu Jeff J. Guo Scott R. Smith
PharmacoEconomics, Vol. 22, Iss. 18, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Modelling outcomes and costs of HIV/AIDS therapy
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 360, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Indirect costs of HIV/AIDS substantial in Spain
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 433, 2003-01 ,pp. :